Immuneering prices $175M public offering; Sanofi invests $25M in concurrent private placement

Immuneering Corp

Public offering of 18,959,914 shares at $9.23/share; expected gross ~$175M; net proceeds ~$164.1M.
Sanofi subsidiary Aventis to invest $25M via private placement at same price, 2,708,559 shares.
Combined net proceeds ~$187.4M; cash runway extended into 2029; closing expected Sep 26, 2025.
Company reduced ATM program by $1.25M and suspended sales under that amount.
Proceeds to advance preclinical/clinical development and for general corporate purposes.

item 1.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.